Conference Coverage

Long-acting all-injectable HIV therapy successful in phase 2b

Publish date: August 28, 2016

 

AT AIDS 2016

References

His study was funded by the Bill and Melinda Gates Foundation.

Dr. Margolis is an employee of Viiv Healthcare, the LATTE-2 study sponsor.

bjancin@frontlinemedcom.com

Pages

Recommended Reading

Antiretroviral efavirenz linked to increased suicidality
MDedge Internal Medicine
Extreme alcohol use worsens HIV disease
MDedge Internal Medicine
Cancer trends shifting in HIV-positive patients
MDedge Internal Medicine
Anal cancer in HIV-infected patients: to screen or not?
MDedge Internal Medicine
Better use of lab testing tools needed to beat HIV/AIDS
MDedge Internal Medicine
HIV research update: Early August 2016
MDedge Internal Medicine
Integrated PrEP and ART prevents HIV transmission in couples
MDedge Internal Medicine
Ombitasvir/paritaprevir-based HCV regimens perform well in HIV coinfection
MDedge Internal Medicine
With HIV PrEP, benefits outweigh resistance risk
MDedge Internal Medicine
Major depressive disorder increases acute MI risk in HIV
MDedge Internal Medicine